[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335462-105":59,"doc-detail-335462-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","nanomedicine-strategies-utilizing-lipid-based-nanoparticles-for-liver-cancer-therapy-exploring-signaling-pathways-and-therapeutic-modalities","Nanomedicine Strategies Utilizing Lipid-Based Nanoparticles for Liver Cancer Therapy - Exploring Signaling Pathways and Therapeutic Modalities","","Liver cancer, especially hepatocellular carcinoma (HCC), remains highly lethal, with limited overall survival and persistent challenges in delivering effective drugs to diseased tissue. The review synthesizes current evidence on lipid-based nanoparticles (LNPs) as advanced nanomedicine platforms for anti-HCC therapy. It highlights how LNP structural configurations improve physical stability and support diverse cargo types with different hydrophobicity and mechanical properties. By connecting signaling pathway insights with therapeutic modality development, the article outlines potential future directions and advancements for targeted drug delivery and improved treatment strategies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nanomedicine-strategies-utilizing-lipid-based-nanoparticles-for-liver-cancer-therapy-exploring-signaling-pathways-and-therapeutic-modalities/335462/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nanomedicine-strategies-utilizing-lipid-based-nanoparticles-for-liver-cancer-therapy-exploring-signaling-pathways-and-therapeutic-modalities/335462.png","ImageObject",300,407,{"name":92,"@type":93},"Skyler","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is effective drug delivery to HCC difficult?","Question",{"text":112,"@type":113},"Pathophysiological changes in the liver cancer environment hinder delivery to the cancerous tissue, even when multiple systemic and local treatments exist.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What advantages do lipid-based nanoparticles (LNPs) provide for liver cancer therapy?",{"text":117,"@type":113},"LNPs offer multiple structural configurations that enhance physical stability and can carry diverse therapeutic cargos with different hydrophobicity and mechanical properties.",{"name":119,"@type":110,"acceptedAnswer":120},"Which signaling and therapeutic directions does the review emphasize for anti-HCC development?",{"text":121,"@type":113},"The review focuses on exploring signaling pathways relevant to HCC and linking these insights to therapeutic modalities that can be advanced using LNP-based delivery.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335462,1790146590,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},2336464648746,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Adv Pharm Bull, 2024, 14(3), 513-523 doi: 10.34172/apb.2024.061  \n[https://apb.tbzmed.ac.ir](https://apb.tbzmed.ac.ir)  \nTUOMSP RESS  \nReview Article  \nNanomedicine Strategies Utilizing Lipid-Based Nanoparticles for Liver Cancer Therapy: Exploring Signaling Pathways and Therapeutic Modalities  \nFereshteh Asgharzadeh1 ID , Maryam Moradi Binabaj2, Sahar Fanoudi3, William C. Cho4, Yu-jeong Yang5, Maryam Azarian6,  \nMehdi Shafiee Ardestani7, Nasim Nasiri8, Marzieh Ramezani Farani5\\#* ID , Yun Suk Huh5\\#* ID  \n1Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.  \n2 Department of Nutrition, Food Sciences and Clinical Biochemistry, School of Medicine, Social Determinants of Health Research Center, Gonabad University of Medical Science, Gonabad, Iran.  \n3 Department of Basic Medical Sciences, Neyshabur University of Medical Sciences, Neyshabur, Iran.  \n4 Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong.  \n5 NanoBio High-Tech Materials Research Center, Department of Biological Sciences and Bioengineering, Inha University, Incheon 22212, Republic of Korea.  \n6 Department of Radiology, Charité -Universitätsmedizin Berlin, Berlin, Germany.  \n7 Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.  \n8 Department of Cell and Molecular Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran.  \nArticle info  \nArticle History:  \nReceived: May 14, 2024  \nRevised: July 3, 2024  \nAccepted: July 29, 2024  \nepublished: July 31, 2024  \nKeywords:  \nLiver cancer, Hepatocellular carcinoma, Signaling pathways, Therapeutic approaches, Lipid-based nanoparticles, Nanomedicine  \nAbstract  \nLiver cancer, specifically hepatocellular carcinoma (HCC), is the second leading cause of cancer-related deaths, following pancreatic cancer. The 5-year overall survival rate for HCC remains relatively low. Currently, there are multiple treatment options available for HCC, including systemic drugs, minimally invasive local therapies such as radiofrequency ablation, transarterial chemoembolization (TACE), and arterial radioembolization (TARE), as well as surgical interventions like liver resection or transplantation. However, the effectiveness of drug delivery to the cancerous liver is hindered by pathophysiological changes in the organ. In order to address this challenge, lipid-based nanoparticles (LNPs) have emerged as promising platforms for delivering a diverse range of therapeutic drugs. LNPs offer various structural configurations that enhance their physical stability and enable them to accommodate different types of cargo with varying mechanical properties and degrees of hydrophobicity. In this article, we provide a comprehensive review of the current applications of LNPs in the development of anti-HCC therapies. By examining the existing research, we aim to shed light on the potential future directions and advancements in this field.  \nIntroduction  \nLiver cancer is projected to cause over one million deaths by 2030, according to the World Health Organization (WHO) .1 The United States has observed a significant 43% increase in liver cancer mortality between 2000 and 2016.2 Hepatocellular carcinoma (HCC), the second leading cause of fatal malignancy after pancreatic cancer, has an overall 5-year survival rate of only 18% .3 In 2020, primary liver cancers (PLCs) were estimated to account for 830,180 cancer deaths and 905,677 new cases worldwide, ranking them as the third most common diagnosed diseases. The highest incidence rates were reported in Eastern and South-Eastern Asia, as well as Northern and Western Africa.4 HCC is the most prevalent  \ntype of PLC globally, accounting for nearly 90% of all liver cancer cases,5 while cholangiocarcinoma (CCA) is the second most common form. CCA is a highly lethal malignancy with a 5-year survival rate of less than 10% . It is classified into intrahepatic (iCCA), peripheral (pCCA), and dist","cbCaicyBFE5QHG08","https://ap.wps.com/l/cbCaicyBFE5QHG08","pdf",1413228,11,"English","# Introduction\n## Global burden and epidemiology of liver cancer and HCC\n## Current treatment landscape and delivery barriers\n## Rationale for lipid-based nanoparticles\n# Lipid-based nanoparticle platforms for anti-HCC therapy\n## Structural configurations and stability\n## Cargo accommodation and drug delivery considerations\n# Signaling pathway exploration and therapeutic modalities\n## Mechanistic targeting of HCC signaling cascades\n## Therapeutic approach integration\n# Future perspectives","[{\"question\":\"Why is effective drug delivery to HCC difficult?\",\"answer\":\"Pathophysiological changes in the liver cancer environment hinder delivery to the cancerous tissue, even when multiple systemic and local treatments exist.\"},{\"question\":\"What advantages do lipid-based nanoparticles (LNPs) provide for liver cancer therapy?\",\"answer\":\"LNPs offer multiple structural configurations that enhance physical stability and can carry diverse therapeutic cargos with different hydrophobicity and mechanical properties.\"},{\"question\":\"Which signaling and therapeutic directions does the review emphasize for anti-HCC development?\",\"answer\":\"The review focuses on exploring signaling pathways relevant to HCC and linking these insights to therapeutic modalities that can be advanced using LNP-based delivery.\"}]","Nanomedicine Strategies Utilizing Lipid-Based Nanoparticles for Liver Cancer Therapy - Exploring Signaling Pathways and Therapeutic Modalities | PDF",1790011060,28]